<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04001491</url>
  </required_header>
  <id_info>
    <org_study_id>7473</org_study_id>
    <nct_id>NCT04001491</nct_id>
  </id_info>
  <brief_title>Interest of 18F-FDG Positron Emission Tomography in the Management of Fevers and Inflammatory Syndromes</brief_title>
  <official_title>Evaluation of the Interest of 18F-FDG Positron Emission Tomography in the Management of Unexplained Fevers and Inflammatory Syndromes in Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients aged 75 and over represent a heterogeneous population with fragile subjects who have
      a higher risk of poor tolerance to many tests and especially who have a risk of major
      functional loss in the event of hospitalization. It is therefore necessary to adapt our
      prescriptions and not to impose on these patients an examination that is unnecessary. Or on
      the contrary, not to do without, out of ignorance, a minimally invasive examination that
      could be useful to these patients.

      In this study, the investigators wish to evaluate the interest of the Pet-Scan in the
      therapeutic management of these elderly patients
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the interest of the Pet-Scan in the therapeutic management of subjects aged 75 years and over with unexplained fever or inflammatory syndrome.</measure>
    <time_frame>1 month</time_frame>
    <description>That is, to assess whether or not the therapeutic course of action has been modified by this examination, resulting in either the discontinuation or initiation of medical, surgical or radiotherapy treatment</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Inflammation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient treated at the University Hospitals of Strasbourg for a check-up of fever or
        inflammatory syndrome, regardless of the duration of the evolution and the examinations
        already carried out
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patient aged 75 years and over,

          -  Patients cared for at the HUS, in hospital or in consultation, during the defined
             period (from 01/05/2013 to 31/12/2018)

          -  Having had an 18FDG-PET/TDM

          -  For fever or inflammatory syndrome check-ups, regardless of the duration of the
             evolution and the examinations already carried out

          -  Patient who has not expressed opposition to the reuse of their data for the purposes
             of this research.

        Exclusion criteria:

          -  Patient who has expressed opposition to participating in the study

          -  Known explanation for fever or inflammatory syndrome

          -  Subjects under legal protection

          -  Subject under the protection of justice

          -  Subject under guardianship or curatorship

        Translated with www.DeepL.com/Translator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel ANDRES, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Strasbourg, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuel ANDRES, MD, PhD</last_name>
    <phone>33 3 88 11 50 66</phone>
    <email>emmanuel.andres@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carole GREUEZ, MD</last_name>
    <phone>33 3 88 11 50 66</phone>
    <email>carole.greuez@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Médecine Interne, diabète et maladies métaboliques - Médicale B</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuel ANDRES, MD, PhD</last_name>
      <phone>33 3 88 11 50 66</phone>
      <email>emmanuel.andres@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Carole GREUEZ, MD</last_name>
      <phone>33 3 88 11 50 66</phone>
      <email>carole.greuez@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Emmanuel ANDRES, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessio IMPERIALE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole GREUEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2019</study_first_posted>
  <last_update_submitted>June 27, 2019</last_update_submitted>
  <last_update_submitted_qc>June 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Inflammatory syndromes</keyword>
  <keyword>fever</keyword>
  <keyword>Tomography</keyword>
  <keyword>Positron emission at 18F-FDG</keyword>
  <keyword>Elderly patients</keyword>
  <keyword>Internal medicine</keyword>
  <keyword>Pet-Scan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

